GET DAILY SIGNALSCeriBell (CBLL) Posts +30% Revenue Growth in Q3 With Wider Losses
Key Takeaways
- Total revenue reached $29.3 million, up roughly 30% year over year and modestly ahead of the consensus estimate of about $29.2 million.
- GAAP net loss per share was $0.55, wider than the roughly $0.50 loss analysts had projected.
- The active account base grew to 747 hospitals, a net increase of 35 accounts during the quarter.
- Gross margin improved to 90%, up from 88% in the prior-year period, supported by product and subscription growth.
- Operating expenses rose 36% to $46.9 million, driving a net loss of $21.4 million compared with $13.5 million a year earlier.
- Adjusted EBITDA loss widened to $12.1 million from $9.2 million a year ago.
Why This Quarter Matters for CeriBell
CeriBell is a medical technology company developing a point-of-care EEG platform designed to detect seizures quickly and monitor delirium in acute-care environments. The third-quarter results stand out because the firm is positioning 2027 as a key year with several new product introductions ahead. Revenue has continued to expand at a steady pace, yet the increase in operating losses underscores the investment required to build out its commercial team. From what I see, the focus for investors remains on whether account additions and higher utilization per hospital can continue to outpace spending, and whether the expanding set of algorithms will support recurring growth rather than one-off hardware sales.
Quarterly Results in Detail
CBLL reported third-quarter 2026 revenue of $29.3 million, representing roughly 30% growth from $22.6 million in the same period last year and slightly above the consensus estimate of approximately $29.2 million. Product revenue increased 31% to $22.2 million, while subscription revenue rose 28% to $7.1 million. The company finished the quarter with 747 active hospitals, reflecting a sequential gain of 35 accounts, and noted that usage per account rose by a double-digit percentage—the strongest level since its initial public offering. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
On the bottom line, the company recorded a GAAP net loss of $21.4 million, or $0.55 per share, versus a loss of $13.5 million, or $0.37 per share, in the prior-year quarter. The result came in wider than the roughly $0.50 per-share loss analysts had anticipated, largely due to higher operating expenses. Gross margin expanded to 90% from 88% a year earlier. Total operating expenses climbed 36% to $46.9 million, and adjusted EBITDA loss increased to $12.1 million from $9.2 million.
Market Reaction and Investor Focus
Shares of CBLL entered the report with solid momentum, buoyed by repeated quarters of approximately 30% revenue growth and recent regulatory achievements. The mixed outcome—a revenue beat alongside a wider loss—prompts investors to balance top-line resilience against rising costs. Management has indicated that near-term losses stem from intentional spending on commercial infrastructure and upcoming launches, so attention is likely to stay on forward indicators such as account growth, utilization trends, and gross margin rather than the headline loss figure. Key risks include the pace of expense growth and any slippage in the commercialization schedule for new products.
Outlook and Items to Watch
Management highlighted 2027 as a pivotal period, centered on the planned launch of its next-generation hardware platform called Omni. This system will incorporate video, multi-day continuous monitoring, and EKG compatibility. A limited market release is slated for the current quarter, with broader availability targeted for 2027. Investors will probably track how rapidly Omni converts interest into commercial adoption.
The company’s delirium monitoring solution is also advancing toward full launch, aided by new reimbursement dynamics that could broaden its addressable market. These offerings are expected to boost utilization without requiring additional subscription fees, making adoption speed and per-account usage important metrics to follow.
Management anticipates gross margins will hold in the high-80% range and expects interest expense to drop below $1 million annually after a debt refinancing. Updated full-year guidance, the path of operating expenses, and any shifts in the litigation and legal-fee outlook will be worth monitoring as the company weighs growth investments against a widening net loss.
Using Tickeron’s AI Tools in My Research
I often turn to Tickeron’s AI Screener when evaluating companies like this one. It lets me quickly filter stocks by technical patterns, fundamentals, and industry trends, helping surface comparable opportunities in the medical technology space without spending hours on manual checks. The platform’s customizable filters have become a regular part of how I cross-reference growth names and identify potential peers.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CBLL in +10.54% Uptrend, advancing for three consecutive days on October 20, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CBLL advanced for three days, in 95 of 111 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on CBLL as a result. In 21 of 27 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The 10-day RSI Indicator for CBLL moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 12 similar instances where the indicator moved out of overbought territory. In 12 of the 12 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 14 of 21 cases where CBLL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 67%.
The Moving Average Convergence Divergence Histogram (MACD) for CBLL turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 11 similar instances when the indicator turned negative. In 7 of the 11 cases the stock turned lower in the days that followed. This puts the odds of success at 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CBLL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
CBLL broke above its upper Bollinger Band on October 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.066) is normal, around the industry mean (4.204). P/E Ratio (-15.318) is within average values for comparable stocks, (1.723). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (9.009) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. CBLL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CBLL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement